22nd September 2025
16th September 2025
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
26th June 2025
Chris Bardon is featured with UBS CIO Mark Haefele on the AACR Believe in Progress podcast
25th June 2025
āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)
28th May 2025
Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types
31st March 2025
Orna Therapeutics Appoints Joseph Bolen, Ph.D., an MPM BioImpact Entrepreneur Partner, as Chief Executive Officer
28th March 2025
DBV Technologies Announces PIPE of up to $306.9 Million, Led by MPM BioImpact
29th January 2025
Cullinan Therapeutics Announces Primary Endpoint Met in Phase 2b Trial of Zipalertinib
8th January 2025
MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
8th January 2025